KHANDELWAL LABS

OVERVIEW

KLab manufactures, markets and out-licenses patented

Pharmaceutical Formulations, NDDS, niche API’s and chiral
intermediates.

KLab’s major sales are from patented products from in-house R&D.
Cefi-XL our patented antibiotic combination is the No.1 launched
new product in India in last 2 years as per July 2006 IMS report.

KLab has more than 150 patents granted/pending using NDDS,

Nanotechnology, Dendrimers and Chiral Chemistry.

KLab has over 2000 employees. The sales force comprises around
1500 persons who cover 250,000 Doctors, 100,000 Pharmacies
and 1500 Stockists in India every month.

KLab has a unique intelligent monthly incentive system which

enables more than 60% of its sales persons to earn more than 50%
of their salaries by way of incentives.

KLab has launched six speciality divisions operating in different

therapeutic areas, to enable focus on maximum new product
launches.

KLab is a key player in India in the niche areas of oncology,

antibiotics, pain and spasm Management.

KLab is a pioneer to bring oncology products in India and has a

dedicated formulation and API facility focused on the developing
countries. KLab also provides contract manufacturing for more than
10 companies.
KLab is ranked 57th in the Indian Pharmaceutical Industry
As per IMS ORG, & KLab is ranked 26th as per its covered market
and is growing above 30% per annum. Within next 3 years, KLab
plans to be around number 10th rank in its covered market.

HISTORY

Products & » Manufacturer of Formulation,Bulk drugs.

Services
Establishment » 1945
Year
FROM INLICENSING INTO INDIA TO
OUTLICENSING TO THE WORLD.

Past
Created Markets in India

Oncology - Cyclophosphamide, Cisplatin, Bleomycin -

Nippon Kayaku
(Japan) / Asta Medica (Germany).

Pain and Spasm – Camylofin and Methocarbamol -

Asta Medica / A.H.
Robins (USA).

Anaesthetic – Glycopyrrolate – A.H. Robins

Respiratory Stimulants – Doxapram – A.H. Robins.

Iron Supplements – Iron Polymaltose – Hausmann

Laboratories
(Switzerland).

Anti-tussive – Prenoxdiazine – Chinoin (Hungary)

Present
Introduced Patented Products based on NDDS
(Marketed in India and out-Licensed for the
Developing Countries)

Camylofin combinations with Nimesulide/ Diclofenac

– ANAFORTAN
GROUP

Methocarbamol combinations with Diclofenac /

Nimesulide.- ROBI GROUP

Cefixime once a day - CEFI OD.

Cefixime + Cloxacillin + Lactobacillus - CEFI XL.

Future
VISION

MISSION

HEAD OFFICE

CORPORATE OFFICE

KHANDELWAL LABORATORIES PVT. LTD

79/87 D.LADPATH
MUMBAI 400 033, INDIA
PH : (91)(22)23718238/46
Fax : (91)(22)23739381
Email : klab@vsnl.com
info@khandelwallab.com

Human Resource

Email : hrd@khandelwallab.com

Marketing International

PH : (91) (22) 23724214

Email : export@khandelwallab.com

Marketing Domestic

Email : mktg@khandelwallab.com

FINANCIAL HIGHLIGHTS

Firm Type » Private Ltd.

Annual Turnover » 10-100crores
Branches » Rajeha Center & Chinchpokli (H.O.)
R&D

 K - NDDS ( Novel Drug Delivery System)

NDDS Research is focused in the areas of colon delivery, Brain

delivery, osmotically engineered systems controlled delivery,
biologically degradable polymers in controlled drug delivery and
site specific drug delivery for enhanced efficacy and reduced
toxicity.
At present our novel drug delivery systems are being
developed mainly in the therapeutic areas like Antibiotics
Cardiovascular, Respiratory, Oncology and NSAID’S .

aColon Targeted Drug Delivery

Anti Cancer Drugs :

5-Flurouracil, Oxaliplatin Leucovorin

Anti Inflammatory and Anti Spasmodic Drugs :

Mesalazine, Corticosteroids, Camylofin
.
Anti-Protozoal Drugs :
Metronidazole, Tinidazole, Secnidazole

Brain Targeted Drug Delivery

Neurological Drugs :
CNS Drugs, Dopamine

Site Specific Drug Delivery

Anti-cancer Buccal Patches : Bleomycin

Topical Formulations : Methotrexate

Muco Adhesives

Osmotically Engineered Systems

 Gastric Retention Systems
Gastroprokinetic Drugs: Ondansetron

Oral Delivery of Parentrals

Vaccines, Peptides and other Parentrals Drugs

Modified Release Systems

Gastric Retention Systems :

Gliclazide SR Tablets, Metformin and Gliclazide
SR Tablets, Metoprolol SR Tablets

Multiple release Systems :

Cefixime OD Tablets, Cefixime +Cloxaciline+
Lactobacillus Tablets

Matrix & Hydrogel Diffusion Systems :

Ofloxacin OD Tablets, Metformin SR Tablets,
Cefpodoxime Proxetil OD Tablets,

 K - Chirals ( Multi Functional Chiral Pools )

Chiral Synthesis has become important in research and Industry

due to the need for increased pathways for identifying active
enantiomers in the rascemic mixture.
This leads to strong and fast growing range of new chiral
building blocks, chiral catalysts and the increased use of chiral
biotransformation in organic synthesis.

CHIRAL COMPOUNDS

Carbohydrate range

Monosaccharide derivatives.

1, 2-Amino Alcohol

1, 2 –Amino Alcohol Oxazolidinones

 Tartaric acid Derivatives

Oxazolidinones Resolving agents

 K-DENDRIMERS

Dendrimers are an exciting new class of Macromoleculecular

architecture and an important component in the area of nanoscience
and technology

KLab offers cost effective solutions for surface modified

polyamino Dendrimers and their application to cosmetics & antimicrobial
formulations.
Our in-house R&D is engaged in combining the
architecture modification of Dendrimer systems using the concept of
supramolecular chemistry to provide custom made Dendrimers. These
Dendrimers can be conveniently used in cosmetic preparations to treat
varieties of skin conditions. They are also useful in delivery of metal ions
in to the skin. They can be used for targeting drugs to different organs.
They have a vast application in Biotechnology.

 NANOTECHNOLOGY

Patented metal nano particles like gold, iron, silver, copper in

biological cells systems. Silver nano gel is soon going to be launched
for use in burns, wounds, and acne.

Tagging of Antibiotics with Metal Nanoparticles

Potential Areas:

Antiviral agents
Anticancer Agents
Anti Malarial Agents
Diagnostics

Present Research Products:

Cosmetics
Anti Microbials

CLINICAL RESEARCH

KHANDELWAL CLINICAL RESEARCH SERVICES (KCRS ONCO)

KCRS has access to 5 decades of relationships with the

major oncologists and also major oncology institutions in India.
KCRS provides overseas companies, including CROs (Contract
Research Organization), SMOs (Site Management Organization) and
Pharmaceutical Companies with local infrastructure and expertise to
ensure that the trials conducted in India are of the highest quality
complying with ICH GCP Guidelines and done as speedily as
possible.
KCRS has access to clinical co-ordinators experienced in
the field of oncology as also CRC's who can be placed at the sites to
ensure that the trials being done are of the highest standards and
with the best personalized handling of the patients which ensures
minimal dropouts.
Since KCRS has no conflict with any of the CROs and
SMOs we have access to all of them and can draw upon their
services depending upon requirement. This enables us to draw on
expertise available with the various individuals/CROs/SMOs, etc.
available in India. We also have close association with the GCP
training Institutes and GCP trainers.
 Our strength is our specific understanding of oncology, the oncology
institutions, oncologists and the regulatory authorities.

PROOF OF CONCEPT STUDIES

We have tie-ups with Rural State of the Art Hospitals. These hospitals
have a huge population of volunteers and patients with excellent
investigation. We have excellent relations with all the necessary
institutes and authorities. We can arrange Proof of Concept Studies
to establish the basic relations between cause and effect by
appropriate trials done most scientifically and speedily

PRODUCTION FACILITIES

MANUFACTURING.
(WHO – GMP Approved)

GENERAL FORMULATIONS FACILITY.

( For Tablets, Capsules and Liquid Injection )

New facility as per latest international guidelines

Separate AHU system for different areas where product is exposed.

Dust free granulation system.

All the material movement from sifter till compression will be by

bins.

Auto lifting and tilting devices for loading and transfering the
product.

Reverse osmosis system and electronic system for generating

 purified water

Tablets
Form Volume Capacity / day Capacity / month

Tablets Uncoated 2,500,000 30,000,000

General Coated 2,000,000 24,000,000

Liquid injectable facility

Form Volume Capacity / day Capacity / month

Ampoules Up to 5ml 150,000 39,000,000

Ampoules 10 ml 50,000 1,300,000

Vials Up to 20 ml 50,000 1,300,000

Dedicated cephalosporin tablets facility

Form Volume Capacity / day Capacity / month

Tablets Uncoated 400,000 4,800,000

Tablets Coated 400,000 4,800,000

COMPANIES AND SUBSIDIRIES

GLOBAL OPERATION

THERAPEUTIC SEGMENT

Therapeutic Categories

Anaesthetics
Anti-Hypertensive
Anti-Bacterials
NSAID’s
Anti-Osteoporotics
 Anti-Spasmodics
Anti-Diabetic
Skeletal Muscle relaxants
Anti Fungal
Anti-Tussives
Anti-Ulcerants

MAJOR BRANDS

Oncology Formulations
HYDROXYUREA CAPS
BICALUTAMIDE TAB
BLEOMYCIN INJ IFOSFAMIDE FOR INJ
CARBOPLATIN INJ IMATINIB MESYLATE CAPS
CISPLATIN INJ IRINOTECAN HCL INJ
CYCLOPHOSPHAMIDE FOR INJ LIPOSOMAL AMPHOTERICIN HCL INJ
DOXORUBICIN INJ METHOTREXATE TAB
EPIRUBICIN HCL INJ PACLITAXEL INJ
ETOPOSIDE CAPS TAMOXIFEN CITRATE TAB
FLUROURACIL INJ VINCRISTINE SULPHATE INJ
GEMCITABINE HCL FOR INJ

Patented Products
KLab is already marketing some of its patented products through its
various divisions.

ANAFORTAN Group– Combinations with

Antispasmodic
Camylofin DiHCl
ROBI Group – Combinations with Methocarbamol Muscle Relaxants
CEFI Group – Combinations of Cefixime Antibiotic
PRENOXID – Prenoxdiazine HCl Antitussive

Oncology API
KLab has a dedicated oncology facility for manufacturing various
APIs. KLab also has a separate sterile powder manufacturing
facility.

Carboplatin
Cisplatin
Cyclophosphamide
5-Fluorouracil
Gemcitabine
Hydroxyurea
Methotrexate
Tamoxifen

Specialty APIs
KLab is manufacturing these specialty APIs majorly for its own
captive consumption.

Camylofin DiHCl
Doxapram Hydrochloride
Glycopyrrolate
Methocarbamol
Prenoxdiazine Hydrochloride

RECENT DEVELOPMENT
New Facility In Uttaranchal As Per Latest USFDA guidelines.
Manufacturing Unit for General Tablets and Cephalosporin
tablets with full Excise Duty and Sales Tax benefits.

CARERR OPURTUNITIES

KLab manufactures, markets and out-licenses patented

Pharmaceutical Formulations, NDDS, niche API’s and chiral
intermediates

KLab’s major sales are from patented products from in-house

R&D. Cefi-XL our patented antibiotic combination is the No.1
launched new product in India in last 2 years as per July 2006
IMS report.

KLab has more than 150 patents granted/pending using NDDS,

Nanotechnology, Dendrimers and Chiral Chemistry.

KLab has over 2000 employees.

The sales force comprises around 1500 persons who cover
250,000 Doctors, 100,000 Pharmacies and 1500 Stockists in India
every month.

KLab has a unique intelligent monthly incentive system

which enables more than 60% of its sales persons to earn more than
50% of their salaries by way of incentives.

KLab has launched six speciality divisions

operating in different therapeutic areas, to enable focus on maximum
new product launches.
The Board

Mr. R.V.S.Mani ( Whole time Director )

Mr. Sanjeev Khandelwal (Chairman & Managing Director)
Mr. Vijay Goel

CONTACT INFORMATION
Address » 79/87, D.Lad Path, P.o.Box no 7808.
Mumbai - 400033 ( Maharashtra ) - India
Contact Person » Mr. Arun Gothe
Phone (Off.) » 022-23718238, 566, 23719736/43
Web-Site » http://www.kgenix.com
E-mail » it@khandelwallab.com

Philosophy.

The Individual

The individual is at the heart of our creative process. We identify

innovative individuals and partner with them.

The scientist works best in institutions, which facilitate open-ended

thinking. We access the scientists in their own habitat without
dislocating them.

Majority of the brilliant scientists and intellectual property is still

untapped, as conventional thinkers cannot understand the
opportunity.

The companies of the future are still unknown and available.

All the creators of knowledge and wealth shall enjoy the fruits of their
creation fairly.

The internet has made the individual extremely powerful.

We develop our own unique strategies and implement them.

Intellectual Property

Intellectual Property
We create our own intellectual property using brilliant individuals and
the latest technologies.

We have cross-hierarchical multifunctional networks of experts from

within the company and outside institutions to feed our creative
process.
Technology
We use the latest technology to access available knowledge
intelligently using multidisciplinary world class minds to create simple
products with unique benefits.

Nature is largely unknown

Nature is simple. The future solutions have to be simple and efficient
based on these principles. Since only1.5% of Nature is known (1.5%
of the DNA is mapped, 98.5% was termed as Junk DNA which has
now got some function) and a large part of nature is still unknown.

OUR RULE – NO RULES

We have a unique system whereby we question and review all the

rules and keep redefining them as we go along